Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.
2.

Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice.

Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, Klar R, Poslusney M, Rook JM, Daniels JS, Niswender CM, Jones CK, Wood MR, Bowman AB, Lindsley CW, Xiang Z, Conn PJ.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14078-83. doi: 10.1073/pnas.1512812112. Epub 2015 Oct 27.

3.

A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease.

Puigdellívol M, Cherubini M, Brito V, Giralt A, Suelves N, Ballesteros J, Zamora-Moratalla A, Martín ED, Eipper BA, Alberch J, Ginés S.

Hum Mol Genet. 2015 Dec 20;24(25):7265-85. doi: 10.1093/hmg/ddv426. Epub 2015 Oct 12.

4.

The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Chopra R, Shakkottai VG.

Neurotherapeutics. 2014 Oct;11(4):751-63. doi: 10.1007/s13311-014-0289-7. Review.

5.

Role of cerebral cortex in the neuropathology of Huntington's disease.

Estrada-Sánchez AM, Rebec GV.

Front Neural Circuits. 2013 Feb 18;7:19. doi: 10.3389/fncir.2013.00019. eCollection 2013. Review.

6.

Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.

Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR, Naydenov AV, Lin YH, Sun X, Keene CD, Grouzmann E, Muchowski P, Bates GP, Mackie K, Stella N.

Eur J Neurosci. 2013 Feb;37(3):429-40. doi: 10.1111/ejn.12045. Epub 2012 Nov 21.

7.

Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M.

Mol Neurobiol. 2012 Oct;46(2):430-66. doi: 10.1007/s12035-012-8316-3. Epub 2012 Sep 4. Review.

8.

Dysfunction of the ubiquitin ligase Ube3a may be associated with synaptic pathophysiology in a mouse model of Huntington disease.

Maheshwari M, Samanta A, Godavarthi SK, Mukherjee R, Jana NR.

J Biol Chem. 2012 Aug 24;287(35):29949-57. doi: 10.1074/jbc.M112.371724. Epub 2012 Jul 11.

9.

The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP.

Neurobiol Dis. 2012 Jul;47(1):75-91. doi: 10.1016/j.nbd.2012.03.025. Epub 2012 Mar 27.

10.

Abnormal burst patterns of single neurons recorded in the substantia nigra reticulata of behaving 140 CAG Huntington's disease mice.

Murphy-Nakhnikian A, Dorner JL, Fischer BI, Bower-Bir ND, Rebec GV.

Neurosci Lett. 2012 Mar 14;512(1):1-5. doi: 10.1016/j.neulet.2011.12.040. Epub 2012 Feb 3.

11.
12.

Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS.

Neuroscience. 2011 Dec 15;198:252-73. doi: 10.1016/j.neuroscience.2011.08.052. Epub 2011 Aug 27. Review.

13.

Impaired alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking and function by mutant huntingtin.

Mandal M, Wei J, Zhong P, Cheng J, Duffney LJ, Liu W, Yuen EY, Twelvetrees AE, Li S, Li XJ, Kittler JT, Yan Z.

J Biol Chem. 2011 Sep 30;286(39):33719-28. doi: 10.1074/jbc.M111.236521. Epub 2011 Aug 5.

14.

Functional Changes in Neocortical Activity in Huntington's Disease Model Mice: An in vivo Intracellular Study.

Stern EA.

Front Syst Neurosci. 2011 Jun 16;5:47. doi: 10.3389/fnsys.2011.00047. eCollection 2011.

15.

Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.

Zucker B, Kama JA, Kuhn A, Thu D, Orlando LR, Dunah AW, Gokce O, Taylor DM, Lambeck J, Friedrich B, Lindenberg KS, Faull RL, Weiller C, Young AB, Luthi-Carter R.

J Neuropathol Exp Neurol. 2010 Sep;69(9):880-95. doi: 10.1097/NEN.0b013e3181ed7a41.

16.

Dopamine and glutamate in Huntington's disease: A balancing act.

André VM, Cepeda C, Levine MS.

CNS Neurosci Ther. 2010 Jun;16(3):163-78. doi: 10.1111/j.1755-5949.2010.00134.x. Epub 2010 Apr 8. Review.

17.

Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Cepeda C, Cummings DM, André VM, Holley SM, Levine MS.

ASN Neuro. 2010 Apr 7;2(2):e00033. doi: 10.1042/AN20090058. Review.

18.

Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease.

Levine MS, Cepeda C, André VM.

Neuron. 2010 Jan 28;65(2):145-7. doi: 10.1016/j.neuron.2010.01.010. Review.

19.

Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease.

Cummings DM, André VM, Uzgil BO, Gee SM, Fisher YE, Cepeda C, Levine MS.

J Neurosci. 2009 Aug 19;29(33):10371-86. doi: 10.1523/JNEUROSCI.1592-09.2009.

20.

Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease.

Joshi PR, Wu NP, André VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS.

J Neurosci. 2009 Feb 25;29(8):2414-27. doi: 10.1523/JNEUROSCI.5687-08.2009.

Supplemental Content

Support Center